Yu Jiaqi, Yang Ya-Nan, Chen Weiyao, Hu Jiaxin, Jin Zhechuan, Wu Chongming, Li Yuyu
Department of Cardiology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.
Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China.
iScience. 2025 Jul 30;28(9):113247. doi: 10.1016/j.isci.2025.113247. eCollection 2025 Sep 19.
Cardiovascular diseases (CVDs) remain one of the leading causes of death worldwide, imposing a significant societal burden and highlighting the urgent need for effective disease management strategies to reduce mortality and prevent disability. Recently, gut microbiota and its metabolites have been considered as an essential part of human physiology, emphasizing their contributions in CVD development and management. An increasing number of studies have shown that gut microbiota affects the process of CVDs either directly through changes in its composition and function or indirectly through its metabolites, and plays an important role in host physiology and disease development. This review provides a comprehensive overview of how gut microbes and their specific metabolites interact and contribute to the generation and development of CVDs. In addition, the therapeutic potential to treat CVDs by targeting the gut microbiota is also discussed, which may provide promising possibilities for the clinical treatment of CVDs in the future.
心血管疾病（CVDs）仍然是全球主要死因之一，给社会带来了沉重负担，凸显了迫切需要有效的疾病管理策略以降低死亡率和预防残疾。最近，肠道微生物群及其代谢产物被视为人体生理学的重要组成部分，强调了它们在心血管疾病发生和管理中的作用。越来越多的研究表明，肠道微生物群通过其组成和功能的变化直接影响心血管疾病的进程，或通过其代谢产物间接影响，在宿主生理和疾病发展中发挥重要作用。本综述全面概述了肠道微生物及其特定代谢产物如何相互作用并促进心血管疾病的发生和发展。此外，还讨论了通过靶向肠道微生物群治疗心血管疾病的治疗潜力，这可能为未来心血管疾病的临床治疗提供有希望的可能性。
